M. Pirillo

发表

U937-SCID mouse xenografts: a new model for acute in vivo HIV-1 infection suitable to test antiviral strategies.

E. Proietti, F. Belardelli, C. Lapenta, 1997, Antiviral research.

Pharmacokinetics of nelﬁnavir in HIV-1-infected pregnant and nonpregnant women

G. Guaraldi, E. Tamburrini, M. Regazzi, 2006 .

A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients with advanced disease.

D. Francisci, C. Tomino, S. Vella, 1999, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Clinical and immuno-virologic characterization of the efficacy of stavudine, lamivudine, and indinavir in human immunodeficiency virus infection.

M. Clerici, M. Saresella, N. Principi, 1999, The Journal of pediatrics.

Evaluation of a second-generation nucleic acid sequence-based amplification assay for quantification of HIV type 1 RNA and the use of ultrasensitive protocol adaptations.

D. Mcclernon, J. Goudsmit, F. de Wolf, 2000, AIDS research and human retroviruses.

Long-term evaluation of cellular immunity during antiretroviral therapy and immunization with human immunodeficiency virus type 1 (HIV-1) Env glycoprotein in HIV-1-infected persons.

A. Cassone, P. Leone, O. Pontesilli, 1997, The Journal of infectious diseases.

Correlation between changes in plasma HIV RNA levels and in plasma infectivity in response to antiretroviral therapy.

E. Nicastri, M. Andreoni, S. Vella, 1997, AIDS research and human retroviruses.

HIV-1 coreceptor switch during 2 years of structured treatment interruptions

L. Palmisano, M. Giuliano, S. Vella, 2013, European Journal of Clinical Microbiology and Infectious Diseases.

C. Tomino, V. Fragola, M. Floridia, 2002, HIV medicine.

Plasma HIV-1 copy number and in vitro infectivity of plasma prior to and during combination antiretroviral treatment.

C. Tomino, S. Vella, A. Binelli, 2000, Antiviral research.

Saquinavir/zidovudine combination in patients with advanced HIV infection and no prior antiretroviral therapy: CD4+ lymphocyte/plasma RNA changes, and emergence of HIV strains with reduced phenotypic sensitivity.

M. Andreoni, H. Jacobsen, I. Duncan, 1996, Antiviral research.

A Simplified HAART Regimen with Raltegravir and Lamivudine, and Pharmacokinetic Interactions with a Combined Immunosuppressive Therapy with Tacrolimus and Everolimus in an HIV/HCV/HBV/HDV Patient after Liver Transplantation.

S. Vella, A. Giacometti, O. Cirioni, 2014, The West Indian medical journal.

The mutational archive in proviral DNA does not change during 24 months of continuous or intermittent highly active antiretroviral therapy

L. Palmisano, M. Giuliano, S. Vella, 2009, HIV medicine.

Hepatitis B virus mother‐to‐child transmission among HIV‐infected women receiving lamivudine‐containing antiretroviral regimens during pregnancy and breastfeeding

S. Mancinelli, L. Palombi, M. Giuliano, 2015, Journal of viral hepatitis.

A randomized trial comparing the introduction of ritonavir or indinavir in 1251 nucleoside-experienced patients with advanced HIV infection.

M. Moroni, L. Contu, A. Lazzarin, 2000, AIDS Research and Human Retroviruses.

HIV-1 coreceptor switch during 2 years of structured treatment interruptions

L. Palmisano, M. Giuliano, S. Vella, 2013, European Journal of Clinical Microbiology & Infectious Diseases.

Risk factors and occurrence of rash in HIV‐positive patients not receiving nonnucleoside reverse transcriptase inhibitor: data from a randomized study evaluating use of protease inhibitors in nucleoside‐experienced patients with very low CD4 levels (<50 cells/mμL)

C. Tomino, S. Vella, R. Bucciardini, 2004, HIV medicine.